title: Treatment of early-stage Hodgkin lymphoma.
abstract: Hodgkin lymphoma (HL) has become one of the best curable malignancies today. This is particularly true for patients with early-stage disease. Today, most patients in this risk group are treated with a combination of chemotherapy followed by small-field radiotherapy. More recent clinical trials such as the German Hodgkin Study Group (GHSG) HD10 study demonstrated, that even two cycles of ABVD followed by 20 Gy involved-field radiation therapy (IF-RT) are sufficient and result in more than 90% of patients being cured. The current treatment for early unfavorable patients is either four cycles of ABVD plus 30 Gy IF-RT or two cycles of BEACOPPbaseline followed by two cycles of ABVD plus IF-RT. Here, the European Organization for Research and Treatment of Cancer (EORTC) demonstrated that in positron emission tomography (PET)-positive patients after two cycles of ABVD, treatment switched to two cycles of BEACOPPbaseline plus radiotherapy results in significantly improved outcomes. Other aspects including attempts to further reduce intensity of treatment will be discussed.
authors: Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany. Electronic address: a.engert@uni-koeln.de.
authors: Andreas
authors: A
authors: Engert
authors: Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands; Department of Hematology, Radboud University Medical Center Nijmegen, Nijmegen, The Netherlands.
authors: John
authors: J
authors: Raemaekers
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000009:adverse effects; D006689:Hodgkin Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D016896:Treatment Outcome
keywords: ABVD; Early stage; Hodgkin lymphoma; Interim PET; Positron emission tomography (PET)